The Global Exchange States Its Case

Global Exchange was set up last winter by five of the largest med-surg companies to make sure they had a role in shaping the future of e-commerce and hospitals. For several months it was reticent but now its new general manager is explaining its mission to provide a single centralized portal for e-procurement to hospitals and integrated delivery systems that results in greater efficiency and savings for hospitals. A major reason for its formation was the concern that established, private-investor-led dot.coms, such as Medibuy and Neoforma.com, were trying to squeeze manufacturers. But the Global Exchange raised concerns among the very manufacturers it was set up to protect--for example, how it would handle competitors and whether each member get the same terms as the others. The exchange has five founding partners, but it is open to all, and all suppliers pay a subscription fee, based on the volume of business they do through the exchange. So far, 40 hospitals have signed up to use the system, which will go on line this fall and the system offers more than 60% of all med-surg supplies on the market. While dot.coms have taken a beating in the stock market in recent months, the Global Health Exchange says it isn't beholden to Wall Street because it has no plans to go public. It is in this business for the long-term, despite the ups and downs of competitors.

Formed in March, at the zenith of the dot-com e-procurement craze, the Global Health Care Exchange LLC purports to be a voice for medical supply manufacturers. Unlike other B2B e-commerce companies, such as Neoforma.com Inc. and medibuy.com Inc. , which were founded by private investors and venture capitalists, the Global Health Care Exchange is the brainchild of five of the largest health care suppliers. By capitalizing on long-standing relationships and clout in the marketplace, these manufacturers figured they'd know better how to serve hospital customers than start-ups driven by financial backers.

More to the point, the product companies were seeking a greater say in how an Internet-enabled hospital supply chain would...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business Strategy

Mapping Biopharma’s AI Strategy: From Custom Datasets to Foundation Models

 
• By 

Biotech companies are pursuing diverse AI strategies beyond expensive custom data generation: foundation model fine-tuning, data-efficient computational methods and targeted proprietary datasets. In Vivo takes a look at some examples.

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By 

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.

AI In Drug Discovery: The Patent Implications

 
• By 

A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.

More from In Vivo

Wide Of The Mark: ‘The Worst EU Medtech Predictions Have Not Come True’

 
• By 

Jana Grieb, European regulatory and market access legal expert at McDermott Will & Emery, explains why the healthtech and pharma industries are warming to the new EU health commissioner as he faces calls to make the MDR more “user friendly.”

This Belgian Biotech’s Drug Cocktail Could Help Reverse Muscle Aging

 
• By 

While big pharma pours billions into creating new anti-aging molecules, a Belgian startup has taken a different path: combining existing safe drugs with AI precision. The early results suggest it might be onto something revolutionary.

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By 

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy